Company Profiles

driven by the PitchBook Platform

Aprea

Aprea
2003 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Series B LATEST DEAL TYPE
$30M LATEST DEAL AMOUNT
$34M TOTAL AMOUNT RAISED
Description

Developer of target-specific drugs intended to be used for the treatment of cancer with non-functional p53. The company's target-specific drugs are focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53, enabling cancer patients to avail innovative therapies for the treatment of cancer.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
Karolinska Institutet Science Park
Nobels väg 3
171 65 Solna
Sweden

+46 (0)8 508 84 50 4
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aprea’s full profile, request a free trial.

Aprea Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 09-Mar-2016 $30M $34M 000.00 Completed Generating Revenue
2. Later Stage VC 13-Feb-2013 00.000 Completed Generating Revenue
1. Early Stage VC 06-Nov-2007 $3.95M $3.95M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding request access »

Aprea Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
HealthCap Venture Capital Minority 000 0000 000000 0
Industrifonden Venture Capital Minority 000 0000 000000 0
Karolinska Development Venture Capital Minority 000 0000 000000 0
Praktikerinvest Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Aprea Executive Team (10)

Name Title Board
Seat
Contact
Info
Christian Schade Board Member, President & Chief Executive Officer
Kimmo Sinervo Chief Financial Officer, Executive, Business Administration & Consultant
Lars Abrahmsen Ph.D Chief Scientific Officer & Senior Vice President
Galina Selivanova Co-Founder & Deputy Director
Ninus Caram-Lelham Ph.D Director, Pharmaceutical Development
You’re viewing 5 of 10 executives. Get the full list »

Aprea Board Members (10)

Name Representing Role Since Contact
Info
Bernd Seizinger Ph.D Self Chairman 000 0000
Brian Daniels MD 5AM Ventures Board Member 000 0000
Guido Magni MD Versant Venture Management Board Member 000 0000
Johan Christenson Ph.D HealthCap Board Member 000 0000
Jonathan Hepple Ph.D Rosetta Capital(London) Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »